Not yet recruiting
Cilostazol for Prevention of Recurrent Stroke Trial
NCT07174414· Phase 3· Stanford University· Source
Contact: Jenny Babka
Active, not recruiting
Postpartum Home Visiting (HEART at Home)
NCT07833904· Washington University School of Medicine· Source
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· Phase 1/2· Pfizer· Source
Recruiting
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
NCT07404852· Washington University School of Medicine· Source
Contact: Angela Birke, MS
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· Phase 2/3· Pfizer· Source
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· Phase 1/2· Pfizer· Source
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383· Vascutek Ltd.· Source
Contact: Study Coordinator
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012· Phase 1/2· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT06779630· Teleflex· Source
Contact: BIOFLOW-48 Project Manager
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246· Phase 3· Joseph Broderick, MD· Source
Contact: Peter D Panagos, MD
Recruiting
StrokeNet Thrombectomy Endovascular Platform
NCT06289985· Medical University of South Carolina· Source
Contact: Jordan Elm
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662· Phase 1· Pfizer· Source
Recruiting
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
NCT05907629· Yale University· Source
Contact: Alyssa Hiserote
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
Strategy for Improving Stroke Treatment Response
NCT05948566· Phase 2· Translational Sciences, Inc.· Source
Contact: Charles Kircher, MD
Recruiting
Feasibility and Acceptability of HCV Treatment in Pregnancy
NCT06367465· Washington University School of Medicine· Source
Contact: Tracey Bach
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429· Cook Research Incorporated· Source
Contact: John Ohman, MD
Recruiting
Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck
NCT05484115· Rijnstate Hospital· Source
Contact: L Sanchez, MD (principal investigator)
Active, not recruiting
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127· Phase 1/2· Pfizer· Source
Active, not recruiting
A Study of Daratumumab
NCT05438043· Phase 3· Janssen Research & Development, LLC· Source
Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Active, not recruiting
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172· Phase 3· University of Florida· Source
Active, not recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883· Phase 3· Joseph Broderick, MD· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046· Phase 3· Yale University· Source
Contact: Yan Wang, MD
Active, not recruiting
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· Phase 3· Pfizer· Source
Active, not recruiting
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03899649· Angiodynamics, Inc.· Source
Active, not recruiting
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
NCT03108456· Abbott Medical Devices· Source
Active, not recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Priscilla Brastianos, MD
Active, not recruiting
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
NCT02000115· Abbott Medical Devices· Source